| 22/12/25 | 07:00:08 | 22 Dec 2025 | | Update on LATIFY Phase III trial of ceralasertib |
| 19/12/25 | 11:00:00 | 19 Dec 2025 | | Director/PDMR Shareholding |
| 16/12/25 | 07:05:00 | 16 Dec 2025 | | Subcutaneous Saphnelo approved in EU |
| 16/12/25 | 07:00:08 | 16 Dec 2025 | | Enhertu approved in US for 1L HER2+ metastatic BC |
| 04/12/25 | 15:00:00 | 4 Dec 2025 | | Holding(s) in Company |
| 01/12/25 | 15:05:00 | 1 Dec 2025 | | Block listing Interim Review |
| 01/12/25 | 15:00:00 | 1 Dec 2025 | | Total Voting Rights |
| 26/11/25 | 07:00:14 | 26 Nov 2025 | | Imfinzi approved in US for early gastric cancer |
| 24/11/25 | 07:00:11 | 24 Nov 2025 | | AstraZeneca manufacturing investment in Maryland |
| 20/11/25 | 07:00:15 | 20 Nov 2025 | | Koselugo (selumetinib) approved in the US |
| 17/11/25 | 15:00:01 | 17 Nov 2025 | | Holding(s) in Company |
| 14/11/25 | 11:00:00 | 14 Nov 2025 | | Director/PDMR Shareholding |
| 10/11/25 | 15:00:00 | 10 Nov 2025 | | Director/PDMR Shareholding |
| 06/11/25 | 07:00:10 | 6 Nov 2025 | | 9M and Q3 2025 results |
| 03/11/25 | 16:00:00 | 3 Nov 2025 | | Result of General Meeting |
| 03/11/25 | 15:00:01 | 3 Nov 2025 | | Total Voting Rights |
| 28/10/25 | 07:05:00 | 28 Oct 2025 | | Director Declaration |
| 28/10/25 | 07:00:09 | 28 Oct 2025 | | Koselugo (selumetinib) approved in the EU |
| 22/10/25 | 07:00:09 | 22 Oct 2025 | | Tezspire Approved in EU for CRSwNP |
| 20/10/25 | 07:05:00 | 20 Oct 2025 | | US FDA Approves Tezspire in CRSwNP |
| 20/10/25 | 07:00:05 | 20 Oct 2025 | | Positive CHMP opinion for subcutaneous Saphnelo |
| 13/10/25 | 07:00:05 | 13 Oct 2025 | | Agreement with US Govt to lower medicine prices |
| 07/10/25 | 07:00:09 | 7 Oct 2025 | | Baxdrostat met primary endpoint in Bax24 Ph3 trial |
| 06/10/25 | 07:30:01 | 6 Oct 2025 | | Datroway improved OS and PFS in TROPION-Breast02 |
| 01/10/25 | 15:00:01 | 1 Oct 2025 | | Total Voting Rights |
| 29/09/25 | 07:30:01 | 29 Sept 2025 | | Enhertu improved IDFS in early BC in DB-05 |
| 29/09/25 | 07:00:17 | 29 Sept 2025 | | AZN harmonises listing structure |
| 25/09/25 | 16:30:00 | 25 Sept 2025 | | Director/PDMR Shareholding |
| 22/09/25 | 07:05:00 | 22 Sept 2025 | | Koselugo recommended for EU approval |
| 22/09/25 | 07:00:12 | 22 Sept 2025 | | Tezspire Recommended for Approval in EU for CRSwNP |
| 17/09/25 | 07:05:00 | 17 Sept 2025 | | Saphnelo met primary endpoint in TULIP-SC |
| 17/09/25 | 07:00:12 | 17 Sept 2025 | | Update on RESOLUTE Phase III trial |
| 01/09/25 | 15:00:00 | 1 Sept 2025 | | Total Voting Rights |
| 28/08/25 | 15:00:00 | 28 Aug 2025 | | Holding(s) in Company |
| 26/08/25 | 15:00:00 | 26 Aug 2025 | | Holding(s) in Company |
| 21/08/25 | 15:00:00 | 21 Aug 2025 | | Holding(s) in Company |
| 18/08/25 | 15:00:00 | 18 Aug 2025 | | Director/PDMR Shareholding |
| 15/08/25 | 15:00:01 | 15 Aug 2025 | | Holding(s) in Company |
| 12/08/25 | 15:00:00 | 12 Aug 2025 | | Holding(s) in Company |
| 01/08/25 | 15:00:01 | 1 Aug 2025 | | Total Voting Rights |
| 29/07/25 | 07:00:12 | 29 Jul 2025 | | H1 and Q2 2025 results |
| 24/07/25 | 07:00:10 | 24 Jul 2025 | | Gefurulimab nanobody met Phase III endpoints |
| 22/07/25 | 07:00:07 | 22 Jul 2025 | | AstraZeneca plans to invest $50bn in the US |
| 16/07/25 | 07:00:07 | 16 Jul 2025 | | Update on anselamimab in AL amyloidosis |
| 14/07/25 | 07:00:11 | 14 Jul 2025 | | Baxdrostat met primary endpt in BaxHTN PhIII trial |
| 04/07/25 | 07:00:06 | 4 Jul 2025 | | Imfinzi approved in the EU for bladder cancer |
| 01/07/25 | 15:00:00 | 1 Jul 2025 | | Total Voting Rights |
| 24/06/25 | 07:00:08 | 24 Jun 2025 | | Datroway approved in US for EGFRm lung cancer |
| 17/06/25 | 11:45:00 | 17 Jun 2025 | | Holding(s) in Company |
| 13/06/25 | 09:30:00 | 13 Jun 2025 | | AstraZeneca enters into collaboration with CSPC |
